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Abstract
Summary We explored the cardiac safety of the osteoporosis
treatment strontium ranelate in the UK Clinical Practice Re-
search Datalink. While known cardiovascular risk factors like
obesity and smoking were associated with increased cardiac
risk, use of strontium ranelate was not associated with any
increase in myocardial infarction or cardiovascular death.
Introduction It has been suggested that strontium ranelate
may increase risk for cardiac events in postmenopausal oste-
oporosis. We set out to explore the cardiac safety of strontium
ranelate in the Clinical Practice Research Datalink (CPRD)
and linked datasets.
Methods We performed a nested case–control study. Primary
outcomes were first definite myocardial infarction,
hospitalisation with myocardial infarction, and cardiovascular
death. Cases and matched controls were nested in a cohort of
women treated for osteoporosis. The association with expo-
sure to strontium ranelate was analysed by multivariate con-
ditional logistic regression.
Results Of the 112,445 women with treated postmenopausal
osteoporosis, 6,487 received strontium ranelate. Annual inci-
dence rates for first definite myocardial infarction (1,352
cases), myocardial infarction with hospitalisation (1,465
cases), and cardiovascular death (3,619 cases) were 3.24,
6.13, and 14.66 per 1,000 patient-years, respectively. Obesity,
smoking, and cardiovascular treatments were associated with
significant increases in risk for cardiac events. Current or past
use of strontium ranelate was not associated with increased
risk for first definite myocardial infarction (odds ratio [OR]
1.05, 95 % confidence interval [CI] 0.68–1.61 and OR 1.12,
95 % CI 0.79–1.58, respectively), hospitalisation with myo-
cardial infarction (OR 0.84, 95 % CI 0.54–1.30 and OR 1.17,
95 % CI 0.83–1.66), or cardiovascular death (OR 0.96, 95 %
CI 0.76–1.21 and OR 1.16, 95 % CI 0.94–1.43) versus pa-
tients who had never used strontium ranelate.
Conclusions Analysis in the CPRD did not find evidence for a
higher risk for cardiac events associated with the use of
strontium ranelate in postmenopausal osteoporosis.
Keywords Cardiac safety . CPRD . Nested case–control
study . Postmenopausal osteoporosis . Strontium ranelate
Introduction
Strontium ranelate has been in clinical use since 2004 for the
management of postmenopausal osteoporosis, for which it
reduces the risk of vertebral and nonvertebral fracture [1, 2].
A related article can be found at DOI 10.1007/s00198-013-2469-4; a
related editorial at DOI 10.1007/s00198-013-2583-3.
C. Cooper (*)
MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton SO16 6YD, UK
e-mail: cc@mrc.soton.ac.uk
C. Cooper
NIHR Nutrition Biomedical Research Centre, University of
Southampton, Southampton, UK
C. Cooper
NIHR Musculoskeletal Biomedical Research Unit,
University of Oxford, Oxford, UK
K. M. Fox
NHLI Imperial College, ICMS, Royal Brompton Hospital,
London, UK
J. S. Borer
Division of Cardiovascular Medicine, The Howard Gilman Institute
for Heart Valve Disease, State University of New York Downstate
Medical Center, Brooklyn, NY, USA
J. S. Borer
The Schiavone Institute for Translational Cardiovascular Research,
State University of New York Downstate Medical Center,
Brooklyn NY, USA
Osteoporos Int (2014) 25:737–745
DOI 10.1007/s00198-013-2582-4
More recently, it has also been approved for the management
of osteoporosis in men at increased risk of fracture [3], and
tested in patients with osteoarthritis [4, 5]. A large number of
phase 2 and 3 clinical trials have been carried out, including
more than 8,000 patients on strontium ranelate with nearly
36,000 patient-years of exposure [6]. A recent pooled analysis
in 7,572 postmenopausal women (3,803 strontium ranelate
and 3,769 placebo) indicated an increased risk for myocardial
infarction (MI) with strontium ranelate, with estimated annual
incidences of 5.7 cases per 1,000 patient-years versus 3.6
cases per 1,000 patient-years with placebo [6]. This translates
into an odds ratio (OR) for MI of 1.60 (95 % confidence
interval [CI], 1.07–2.38) for strontium ranelate versus placebo
(incidences of 1.7 % versus 1.1 %, respectively) [6]. Among
the cases of MI, fatal events were less frequent with strontium
ranelate (15.6 %) than with placebo (22.5 %). In order to
reduce the risk in treated patients in routine clinical practice,
new contraindications have been proposed for strontium
ranelate in patients with a history of cardiovascular disease
(history of ischaemic heart disease, peripheral artery disease,
and cerebrovascular disease, and uncontrolled hypertension)
[7]. Exclusion of patients with these contraindications from
the pooled analysis mitigated the risk for MI (OR, 0.99; 95 %
CI, 0.48–2.04; data on file).
There has been no suggestion of excessive cardiac events
in postmarketing surveillance data for strontium ranelate cov-
ering more than 3.4 million patient-years of treatment from
September 2004 to February 2013. There have been 16 cases
of MI spontaneously reported over the 96-month period of
monitoring, i.e. a rate of 0.5 cases per 100,000 patient-years
[6]. Similarly, an observational prospective cohort study in-
cluding 12,076 patients on strontium ranelate with 80 % ad-
herence over 2 years did not support increased incidence of
cardiac events over the 32.0±9.7 months of follow-up; there
were 33 cases of MI in the cohort (1.3 per 1,000 patient-years)
[6, 8].
In this paper, we describe a nested case–control study
performed within the UK Clinical Practice Research Datalink
(CPRD) apparatus to further explore the risk for ischaemic
cardiac events associated with the use of strontium ranelate in




The main data source for this nested case–control study was
the CPRD, which comprises anonymous electronic medical
records from primary care in the UK and covers about 8 % of
the population. Contributing CPRD physicians come from
some 640 practices throughout the UK, which must meet
specific up-to-standard (UTS) reporting requirements defined
by the CPRD. The accuracy and completeness of the CPRD
dataset has been confirmed [9, 10], as has the predictive value
of the database for cardiac events, including MI [11, 12]. The
positive predictive value of the CPRD to detect acute MI, for
example, is 93 % (95 % CI, 90–96 %), i.e. the proportion of
cases with acute MI codes that are confirmed as true cases of
acute MI [12]. In our study, according to the outcome ex-
plored, the CPRD data were linked to the Hospital Episode
Statistics (HES) and the Office of National Statistics (ONS)
databases to obtain additional information on hospitalisations
and fatalities, respectively. The study protocol was approved
by the Independent Scientific Advisory Committee of the
Medicines and Healthcare Products Regulatory Agency
(MHRA).
We identified all male and female patients who had re-
ceived a prescription for osteoporosis treatment or a medical
record of primary osteoporosis between 1 January 2002 and
30 April 2012. The cohort entry date was fixed as the date of
the first prescription of osteoporosis treatment during the
study period. Patients were excluded if they had had a pre-
scription for an osteoporosis treatment in the previous year or
had received a prescription for bisphosphonate for indications
other than osteoporosis (e.g., Paget’s disease, hypercalcaemia,
breast cancer, or myeloma). Patients could also be excluded if
they came from a practice with less than 1 year of UTS CPRD
data at their cohort entry date. From this population, we then
excluded successively patients who had never received a
treatment for their osteoporosis, and then all male patients,
to reach a population of women with treated osteoporosis.
The follow-up period extended from the cohort entry date
to the date of the last data collection from the practice, the date
of transfer if the patient left the practice, or the date of death.
Outcomes and selection of controls
The primary outcomes of our nested case–control study were
first definite MI (fatal or nonfatal), hospitalisation with MI
(fatal or nonfatal, first or subsequent), and cardiovascular
death occurring after the cohort entry date. The index date
for cases was defined as the date of event. Cases of MI were
qualified as definite [13] if there was a CPRD record of MI,
and the patient either (1) died within 30 days, or (2) was
initiated on relevant treatment (e.g., statins, nitrates, and/or
beta-blockers), and had other supporting evidence (e.g., loca-
tion of infarct, coronary artery revascularisation, and/or ele-
vated cardiac enzymes) within 2 months of the MI. Analyses
on first definite MI excluded patients with previous MI. Cases
of hospitalisation with MI were identified in the HES dataset
in patients eligible for linkage, which ensured detection of
cases not otherwise apparent in the GP record. Analyses of
cases of hospitalisation with MI did not exclude patients with
previous MI. Cases of cardiovascular death were identified in
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the ONS death dataset in patients eligible for linkage. This
dataset provides information on cause and date of death,
which may be missing in the general practice-based CPRD.
Three case–control analyses were performed successively.
Thus, for each case of first definite MI, hospitalisation with MI,
or cardiovascular death, six to ten controls without the event prior
to the index date were randomly selected by risk set sampling
within the treated osteoporosis cohort. The index date attributed
to controls was the same as in the corresponding case. Cases and
controlswerematched on year of birth (exactmatching criterion),
calendar date of event, and prior osteoporosis treatment duration
±1 year (i.e. time since first prescription of any osteoporosis
treatment as a proxy for disease severity).
Treatment exposure
Treatment exposure was calculated on the basis of the records
of prescriptions issued by general practitioners according to
routine clinical practice in the UK [14]. Exposure to strontium
ranelate before the index date was compared between cases
and controls. Similar analyses were performed in patients with
exposure to alendronate as a reference treatment in osteopo-
rosis. Current use was defined as having an ongoing prescrip-
tion for the treatment at the index date (or within the previous
month). Past use was defined as cessation of the treatment
more than 1 month prior to the index date. Patients who had
never had a prescription for the treatment before the index date
were used as a reference group.
Statistical methods
The characteristics of the patients are presented as descriptive
statistics at cohort entry date for women with treated osteopo-
rosis, and at date of treatment initiation for women receiving
strontium ranelate or alendronate. For each outcome, the
annual incidence rate (IR) per 1,000 patient-years was esti-
mated in the cohort of women with treated osteoporosis with
the 95 % confidence interval (CI) based on a Poisson or
normal approximation. The comparisons between cases and
controls were based on a multivariate conditional logistic
regression. We estimated the effect of region, prior UTS
follow-up duration, socioeconomic status, obesity (body mass
index ≥30 kg/m2 or diagnosis), smoking (yes/no), antidiabetic
treatments, statins/fibrates, antihypertensive treatments (beta-
blockers, calcium channel blockers, renin–angiotensin system
inhibitors, and/or diuretics), platelet inhibitors (including as-
pirin), nitrates, hormone replacement therapy, calcium and
vitamin D supplementation, other osteoporosis treatment,
and history of MI. Patients with current use or past use of
strontium ranelate were compared with patients who had
never used strontium ranelate. The odds ratios associated with
the considered treatment effect in the unadjusted and fully
adjusted models were provided as well as their accuracy (two-
sided 95 % CI). Fully adjusted analyses were based on a
backward selection of all factors significant in the univariate
analysis for the outcome in question (20 % threshold). The
same methodology was used to compare patients with current
use or past use of alendronate with patients who had never
Fig. 1 Patient flow. MI
myocardial infarction, UTS
CPRD up-to-standard Clinical
Practice Research Datalink (data)
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used alendronate. All statistical analyses were conducted
using SAS® software version 9.2.
Results
The selection of patients for this nested case–control study is
presented in Fig. 1. Out of over 220,000 patients with a
diagnosis of primary osteoporosis and/or a prescription for
an osteoporosis treatment between 1 January 2002 and 30
April 2012 in the CPRD, we identified a cohort of 112,445
women with treated osteoporosis. At entry to the cohort,
patients were aged 71.8±12.7 years; they had BMI of 25.5±
5.3 kg/m2, and 15 % were classified as obese (Table 1). The
rate of smoking was 20 %. Time since diagnosis of osteopo-
rosis was 21.5±49.2 months. About half were receiving car-
diovascular treatments such as antihypertensives or platelet
inhibitors. Two thirds of the patients were receiving calcium
and vitamin D supplementation.
During the follow-up period, 6,487 patients received stron-
tium ranelate and 94,654 received alendronate. The mean
cumulative exposure for strontium ranelate was 12.8±
16.4 months (with a maximum of 87 months), while that for
alendronate was 25.4±26.0 months. The patients receiving
strontium ranelate were older than the general cohort of wom-
en with treated osteoporosis and had a longer time since
diagnosis; they were also more likely to be receiving concom-
itant supplementation with calcium and vitamin D (Table 1).
There were 1,352 cases of first definite MI in the cohort of
women with treated osteoporosis (IR 3.24 per 1,000 patient-
years; 95 % CI, 3.07–3.41). Of these, 16 cases were excluded
from the analysis due to failure to identify six to ten matching
controls, leaving 1,336 cases and 13,330 matching controls.
The mean age of the cases and controls was 79.5 years with
mean osteoporosis treatment duration of 39 months (Table 2).
Less than 5 % of cases and controls had been previously
exposed to strontium ranelate, while about 80 % had been
exposed to alendronate. The mean cumulative prior exposure
to strontium ranelate was 10.9±13.9 (64 cases, with a maxi-
mum duration of 57 months) and 10.7±13.6 months (615
controls), and the mean cumulative prior exposure of
alendronate was 19.6±21.6 (1,060 cases) and 21.0±
21.5 months (10,494 controls). Results for first definite MI
are presented in Table 2. In the unadjusted analysis, as would
be expected, obesity, smoking, and use of antidiabetics,
statins/fibrates, antihypertensives, and platelet inhibitors were
associated with significant increases in risk for first definite
MI. Current or past use of strontium ranelate was not associ-
ated with an increase in risk for first definite MI compared
with patients who had never received strontium ranelate (ad-
justed OR 1.05, 95 % CI 0.68–1.61 and OR 1.12, 95 % CI
0.79–1.58, respectively). Similar results were found for cur-
rent or past use of alendronate (adjusted OR 0.98, 95 % CI
0.83–1.15 and OR 1.09, 95 % CI 0.92–1.30).
There were 1,465 cases of hospitalisation with MI in the
cohort of women with treated osteoporosis (IR 6.13 per
1,000 patient-years, 95 % CI 5.81–6.44). Of these, 32 cases
were excluded from the analysis (matching failure), and re-
sults for hospitalisation for MI in 1,433 cases and 14,261
matched controls are presented in Table 3. These patients were
Table 1 Characteristics of the co-
hort of women with treated osteo-
porosis at cohort entry date, and for
women receiving strontium ranelate
and women receiving alendronate
at date of initiation of treatment
Values are means±SD or num-
bers (%)
a Cardiovascular procedure or
ischaemic cardiac event (myocar-
dial infarction, acute coronary









N =112,445 N=6,487 N=94,654
Age, years 71.8±12.7 74.9±11.5 72.0±12.5
Body mass index, kg/m2 25.5±5.3 24.6±5.0 25.5±5.3
Smoking 22,820 (20 %) 894 (14 %) 18,554 (20 %)
Characteristics of osteoporosis






Calcium supplementation at entry 75,631 (67 %) 4,786 (74 %) 64,721 (68 %)
Vitamin D supplementation at entry 69,079 (61 %) 4,614 (71 %) 61,139 (65 %)
History of cardiovascular events
Myocardial infarction 4,502 (4 %) 309 (5 %) 3,740 (4 %)
Acute ischaemic cardiac eventa 6,524 (6 %) 447 (7 %) 5,464 (6 %)
Treatments at entry
Antidiabetic agents 6,747 (6 %) 343 (5 %) 5,806 (6 %)
Statins/fibrates 26,510 (24 %) 1,710 (26 %) 23,503 (25 %)
Antihypertensive agents 57,546 (51 %) 3,472 (54 %) 48,861 (52 %)
Platelet inhibitors (including aspirin) 27,381 (24 %) 1,723 (27 %) 23,248 (25 %)
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aged 81.1 years, and <5 % had previously received strontium
ranelate (67 cases and 613 controls) and about 80 %
alendronate (1,130 cases and 11,424 controls). The durations
of prior osteoporosis treatment exposure were very similar to
those reported for the analysis of first definite MI. Obesity,
smoking, and the use of antidiabetics, statins and fibrates,
antihypertensives, and platelet inhibitors were all found to
increase the risk for hospitalisation with MI. There was a
particularly strong association for previous hospitalisation
with MI, which increased risk for recurrent hospitalisation
with MI by almost four times (OR 3.79, 95 % CI 3.16–
4.55). Current or past use of strontium ranelate was not
associated with a significant increase in risk for hospitalisation
with MI (adjusted OR 0.84, 95 % CI 0.54–1.30 and OR 1.17,
95 % CI 0.83–1.66). Patients with current use of alendronate
were at borderline lower risk for hospitalisation with MI than
patients who had never used alendronate (adjusted OR 0.85,
95 % CI 0.73–0.99), though the effect was not found for
patients with past use of alendronate (adjusted OR 1.17,
95 % CI 0.99–1.37).
There were 3,619 cardiovascular deaths in the cohort of
women with treated osteoporosis (IR 14.66 per 1,000 patient-
years, 95 % CI 14.18–15.14). Of these, 103 cases were excluded
from the analysis (matching failure), leaving 3,516 cases, which
were compared with 34,982 matched controls (Table 4). Cases
and controls were aged 83.9 years. The durations of cumulative
prior exposure to strontium ranelate (195 cases and 1,689 con-
trols) and alendronate (2,732 cases and 27,573 controls) were
similar to that described for the analysis of first definite MI.
Obesity, smoking, and use of antidiabetics, statins/fibrates, anti-
hypertensives, and platelet inhibitors were associated with higher
risk for cardiovascular death. Current or past use of strontium
ranelate was not associated with a significant increase in risk for
cardiovascular death versus patients who had never received the
treatment (adjusted OR 0.96, 95 % CI 0.76–1.21, and OR 1.16,
95 % CI 0.94–1.43). Current use of alendronate was associated
with a reduction in the risk for cardiovascular death versus
patients who had never used alendronate (adjusted OR 0.80,
95 % CI 0.72–0.88), while past use was associated with a
borderline increase in risk for cardiovascular death versus
Table 2 Risk for first definite
myocardial infarction associated
with main risk and confounding
factors and osteoporosis treatment
OR odds ratio, CI confidence
interval




per class, antidiabetic treatments,
hormone replacement therapy,
calcium and vitamin D supple-


















No 921 (69 %) 9,651 (72 %) 1 (reference)
Yes 236 (18 %) 1,779 (13 %) 1.40 (1.20–1.63)
Not assessed 179 (13 %) 1,900 (14 %) 0.98 (0.82–1.16)
Smoking status
No 661 (49 %) 8,305 (62 %) 1 (reference)
Yes 262 (20 %) 1,641 (12 %) 2.06 (1.76–2.41)
Not assessed 413 (31 %) 3,384 (25 %) 1.55 (1.36–1.76)
Specific treatments
Antidiabetics 143 (11 %) 837 (6 %) 1.79 (1.49–2.16)
Statins/fibrates 433 (32 %) 3,800 (29 %) 1.21 (1.07–1.37)
Antihypertensives 958 (72 %) 8,133 (61 %) 1.68 (1.48–1.91)
Platelet inhibitors
(including aspirin)
500 (37 %) 4,080 (31 %) 1.38 (1.22–1.55)
Strontium ranelate
Never 1,272 (95 %) 12,715 (95 %) 1 (reference) 1 (reference)
Current 25 (2 %) 263 (2 %) 0.95 (0.63–1.44) 1.05 (0.68–1.61)
Past 39 (3 %) 352 (3 %) 1.11 (0.79–1.55) 1.12 (0.79–1.58)
Alendronate
Never 276 (21 %) 2,836 (21 %) 1 (reference) 1 (reference)
Current 636 (48 %) 6,571 (49 %) 1.00 (0.86–1.16) 0.98 (0.83–1.15)
Past 424 (32 %) 3,923 (29 %) 1.12 (0.95–1.32) 1.09 (0.92–1.30)
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patients who had never used alendronate (adjusted OR 1.11,
95 % CI 1.01–1.23).
Discussion
The purpose of this retrospective observational study using
the UKCPRD and linked datasets was to evaluate whether the
use of strontium ranelate in routine clinical practice is associ-
ated with increased risk for ischaemic cardiac events. This
nested case–control study was based on a cohort
encompassing over 110,000 women treated for osteoporosis,
mostly with alendronate. A small proportion was receiving
strontium ranelate.
In our study, current use of strontium ranelate in patients
with postmenopausal osteoporosis was not associated with
increased risk for first definite MI versus patients who had
never received the treatment. Similar results were found for
hospitalisation with MI and cardiovascular death, and for
patients who had used the treatment in the past. Our results
also suggest that current use of alendronate could have a
cardioprotective effect. This is not the first such finding for
alendronate [15], but the underlying reasons remain unclear,
and the use of a retrospective, observational, case–control
study design, as well as the borderline significance of the
result precludes firm conclusions on this point until further
research is performed.
The mean duration of prior exposure to strontium ranelate
was around 1 year for cases and controls. Although longer-
term exposure is not available in CPRD, these data reflect the
real-life pattern of strontium ranelate use from clinical practice
in the UK.
The robustness of the analysis is demonstrated by the
consistency of our observations over the three outcomes con-
sidered. A number of sensitivity analyses have been per-
formed using various definitions of exposure. These led to
consistent results (data not shown). Moreover, the observation
of the effects of established cardiovascular risk factors, e.g.,
Table 3 Risk for hospitalisation
with myocardial infarction asso-
ciated with main risk and con-
founding factors and osteoporosis
treatment
OR odds ratio, CI confidence
interval




per class, antidiabetics, hormone
replacement therapy, calcium and
vitamin D supplementation, other
osteoporosis treatment, and histo-

















No 1,016 (71 %) 10,341 (73 %) 1 (reference)
Yes 232 (16 %) 1,857 (13 %) 1.28 (1.10–1.49)
Not assessed 185 (13 %) 2,063 (14 %) 0.91 (0.77–1.07)
Smoking status
No 741 (52 %) 8,761 (61 %) 1 (reference)
Yes 247 (17 %) 1,587 (11 %) 1.89 (1.62–2.22)
Not assessed 445 (31 %) 3,913 (27 %) 1.35 (1.20–1.53)
Previous hospitalisation
with myocardial infarction
179 (12 %) 530 (4 %) 3.79 (3.16–4.55)
Specific treatments
Antidiabetics 209 (15 %) 909 (6 %) 2.51 (2.14–2.95)
Statins/fibrates 585 (41 %) 4,077 (29 %) 1.77 (1.58–1.99)
Antihypertensives 1,087 (76 %) 9,138 (64 %) 1.82 (1.60–2.07)
Platelet inhibitors
(including aspirin)
664 (46 %) 4,767 (33 %) 1.76 (1.57–1.97)
Strontium ranelate
Never 1,366 (95 %) 13,648 (96 %) 1 (reference) 1 (reference)
Current 24 (2 %) 280 (2 %) 0.86 (0.56–1.32) 0.84 (0.54–1.30)
Past 43 (3 %) 333 (2 %) 1.29 (0.93–1.79) 1.17 (0.83–1.66)
Alendronate
Never 303 (21 %) 2,837 (20 %) 1 (reference) 1 (reference)
Current 665 (46 %) 7,383 (52 %) 0.84 (0.73–0.97) 0.85 (0.73–0.99)
Past 465 (32 %) 4,041 (28 %) 1.08 (0.93–1.26) 1.17 (0.99–1.37)
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smoking, obesity, and previous hospitalisation with MI, on
subsequent cardiac events [16] supports the validity of our
study. Also, even though there were many risk and confound-
ing factors included in the multivariate analysis, there was
little difference between the adjusted and unadjusted results
for the treatment effect.
There are a number of limitations to our study. Several
possible confounders are not recorded in the CPRD such as
severity of osteoporosis, bone mineral density, menopause,
physical activity, and family history of ischaemic cardiac
events. However, the nested case–control design handles the
heterogeneity of the population (by matching cases with con-
trols using the most important potential confounders and
adjusting the analyses on the remaining risk and confounding
factors). There is a potential for channelling bias due to
confounding by severity of osteoporosis or possible links
between osteoporosis and cardiovascular disease [17]. This
may limit direct comparison between strontium ranelate and
alendronate because strontium ranelate is generally given only
when alendronate is not acceptably effective [14]. Finally,
adherence to treatment may be overestimated since drug pre-
scribing does not necessarily equate with drug use, though
sensitivity analyses using various definitions of drug exposure
gave similar results.
Further caveats to our study include the absence of a
control group without osteoporosis and the use of propensity
matching for our cases and controls. This leaves open the
potential for confounding by indication, with regard to treat-
ment using alendronate or strontium ranelate, following diag-
nosis of osteoporosis. The reduced risk of MI among predom-
inantly alendronate users might represent just such a selection
artefact. Finally, the pattern of osteoporosis prescribing in the
UK [14] left the selected cohort of women treated for osteo-
porosis, as predominantly receiving alendronate (84 %). Only
6 % of the treated women received strontium ranelate; and
only 14 % had never used either strontium ranelate or
alendronate. Thus, the ability to contrast strontium ranelate
treatment with the cardiovascular experience of women in the
UK population as a whole or with women using osteoporosis
treatment other than alendronate was limited. The study
Table 4 Risk for cardiovascular
death associated with main risk
and confounding factors and
osteoporosis treatment
OR odds ratio, CI confidence
interval




per class, antidiabetics, hormone
replacement therapy, calcium and


















No 2,471 (70 %) 25,429 (73 %) 1 (reference)
Yes 433 (12 %) 3,937 (11 %) 1.13 (1.02–1.26)
Not assessed 612 (17 %) 5,616 (16 %) 1.12 (1.02–1.23)
Smoking status
No 2,043 (58 %) 22,146 (63 %) 1 (reference)
Yes 493 (14 %) 3,671 (10 %) 1.49 (1.34–1.66)
Not assessed 980 (28 %) 9,165 (26 %) 1.17 (1.08–1.26)
Specific treatments
Antidiabetics 399 (11 %) 2,201 (6 %) 1.91 (1.71–2.14)
Statins/fibrates 1,215 (35 %) 9,776 (28 %) 1.38 (1.28–1.49)
Antihypertensives 2,774 (79 %) 23,591 (67 %) 1.85 (1.70–2.01)
Platelet inhibitors
(including aspirin)
1,698 (48 %) 12,542 (36 %) 1.69 (1.58–1.82)
Strontium ranelate
Never 3,321 (94 %) 33,293 (95 %) 1 (reference) 1 (reference)
Current 84 (2 %) 777 (2 %) 1.09 (0.86–1.37) 0.96 (0.76–1.21)
Past 111 (3 %) 912 (3 %) 1.22 (1.00–1.50) 1.16 (0.94–1.43)
Alendronate
Never 784 (22 %) 7,409 (21 %) 1 (reference) 1 (reference)
Current 1,584 (45 %) 17,686 (51 %) 0.85 (0.77–0.93) 0.80 (0.72–0.88)
Past 1,148 (33 %) 9,887 (28 %) 1.10 (1.00–1.22) 1.11 (1.01–1.23)
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sample utilised was necessary to maximise the prevalence of
the exposure of interest (strontium ranelate), but future re-
search could include a more traditional retrospective cohort
study in patients treated with strontium ranelate, alendronate,
osteoporosis with other treatments, and women selected from
the CPRD as a whole.
Nonetheless, much effort was made to reduce bias in this
retrospective observational study. The sensitivity of the algorithm
for first definite MI has been tested and confirmed [13], and the
reliability of the identification of cardiac outcomes is further
reinforced by the use of hard endpoints and linkage to ONS/
HES data. The case–control analysis was nested in a cohort of
women who were all treated for osteoporosis to reduce selection
bias due to potential heterogeneity between patients. The design
also accounts for the twomain confounders related to clinical use
of strontium ranelate in the UK [14]: calendar date, because
strontium ranelate has been available for a short time relative to
other osteoporosis treatments, and disease duration, because
strontium ranelate is recommended second or third line, while
alendronate, for example, is usually prescribed first line. This is
clear from the patient characteristics, which show that patients
treated with strontium ranelate were older than the patients with
osteoporosis treatedwith other agents and had a longer time since
diagnosis.
Our study highlights a substantial relative risk for cardiac
events associated with previous hospitalisation with MI in pa-
tients with treated postmenopausal osteoporosis. The current
labeled indication for drug administration according to the Euro-
peanMedicines Agency approval for strontium ranelate includes
a contraindication in patients at risk for cardiovascular events
(history of ischaemic heart disease, peripheral artery disease,
cerebrovascular disease, and uncontrolled hypertension) [7].
Our analysis indicates that the risk for cardiac events is increased
in patients with these contraindications. Indeed, in the case–
control analysis of hospitalisation with MI, 12 % of the cases
and 4 % of the controls had had a history of previous
hospitalisation with MI before index date. Similar elevated risks
were found for history of ischaemic heart disease (71 % in cases
versus 24% in controls), peripheral artery disease (18% in cases
versus 7 % in controls), and cerebrovascular disease (23 % in
cases versus 15 % in controls). In line with this, exclusion of
patients with the contraindications from the pooled analyses of
the randomised-controlled trials with strontium ranelate
completely mitigated the risk for MI (data on file). The new
contraindications for strontium ranelate are therefore expected to
reduce any potential cardiovascular risk associated with use of
this treatment.
Conclusion
The results of this nested case–control study in the CPRD
indicate no evidence for a higher risk of MI or cardiovascular
death associated with the use of strontium ranelate in women
treated for osteoporosis compared with non-use of this agent
in routine medical practice in the UK.
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